Introduction. Secondary bacterial pneumonias are complications responsible for most fatalities following influenza infection, and antiviral drugs are used to prevent their development. The aim of the study is to evaluate the efficacy of tilorone and its combination with antibacterial agents in a murine model of secondary bacterial pneumonia caused by Staphylococcus aureus after influenza infection. Materials and methods. BALB/c mice were infected with influenza virus A/California/04/2009 (pdm H1N1 2009) virus, followed by S. aureus infection four days later. Treatments included the interferon inducer tilorone, comparator oseltamivir, antibacterial agents cefuroxime and amoxicillin, or combinations of antivirals with antibiotics. Efficacy was assessed by increased survival, reduced weight loss, and inhibition of pathogen proliferation in the lungs. Results. The efficacy of tilorone, as indicated by increased survival, reduced weight loss, and decreased pathogen load in the lungs, in a mouse model of secondary bacterial pneumonia following influenza infection, increased with reducing viral dose, and intraperitoneal administration of the drug was more effective than oral administration. The combination of tilorone with the antibiotic cefuroxime, to which S. aureus was sensitive, was more effective than either agent alone and completely protected animals from death and from viral and bacterial proliferation in the lungs. In contrast, the combination with amoxicillin, to which S. aureus was resistant, had no effect on disease outcome. Conclusion. The efficacy of tilorone in this model depended on viral dose and drug administration route. Combining tilorone with cefuroxime was more effective than monotherapy.
Introduction. Pneumococcal diseases remain relevant for the whole world. On the one hand, this is due to the high prevalence of pneumococcus and the other hand, the growth of antibiotic-resistant strains and the constant change of clinically significant serotypes of the pathogen.The aim of the research was to study of the protective activity of a mixture of pneumococcal antigens.Material and methods. we used preparations of a capsular polysaccharide (CPS) obtained from Streptococcus pneumoniae serotype 3; protein-containing fraction (PCF) obtained from an aqueous extract of cells of S. pneumoniae serotype 6B; recombinant pneumolysin (rPly). Mice were immunized intraperitoneally twice with an interval of 14 days with mixtures of bacterial antigens: CPS + PCF; CPS + rPly; PCF + rPly. To assess the protective activity of the studied drugs after double immunization animals were infected intraperitoneally with S. pneumoniae serotype 3. To study the effect of mixtures of bacterial preparations on the infectious process in the lungs immunized mice were infected with S. pneumoniae serotype 3. The humoral immune response was studied with IgG using the method of ELISA.Results. The CPS + rPly mixture protected mice from intraperitoneal infection with S. pneumoniae serotype 3 regardless of the infecting dose. Immunization with CPS + PCF or CPS + rPly mixtures influenced a significant decrease the number of seeded bacterial cells from lungs during the entire observation period (72 h) compared to the control. Administration of mixtures of bacterial antigens of CPS + PCF, CPS + rPly or PCF + rPly to animals led to a significant increase of the level of antibodies to all antigens, however, the highest levels of IgG were determined to PCF and rPly.Conclusion. The results obtained suggest that different antigenic drugs in mixtures affect different mechanisms of immunity activation.
Background/Objectives: Acute respiratory infections represent a global health burden due to their high incidence, morbidity and mortality. Despite advances in prevention and treatment, strategies providing broad protection against respiratory pathogens remain limited. This study evaluated the antiviral activity of nasal spray forms based on an antigen complex from opportunistic bacteria, with or without a mucoadhesive copolymer, and their influence on cellular and humoral components of the immune response. Methods: Antiviral activity was assessed in experimental models of SARS-CoV-2 infection in Syrian hamsters and influenza A pneumonia in mice under prophylactic and therapeutic–prophylactic regimens. Parameters of cellular and humoral immune response were assessed using delayed-type hypersensitivity, antibody-forming cell assays, and leukocyte phagocytic activity. Results: Both forms showed comparable influence on cellular and humoral components of the immune response. In a mouse model of lethal influenza pneumonia induced by A/California/04/2009 (H1N1)pdm09 virus, intranasal administration at 100 µg/kg increased mean survival time and survival rate, and reduced body weight loss. In SARS-CoV-2-infected hamsters, both forms reduced clinical signs, body weight loss, weight lung index, lung pathology, and decreased viral titers. The copolymer-containing form showed the most pronounced effect under the therapeutic–prophylactic regimen, with greater protection against body weight loss and stronger suppression of viral replication. Conclusions: The findings support further investigation of these nasal spray forms as candidates for prophylaxis and adjunctive therapy of respiratory infections, particularly when pathogen variability may limit the effectiveness of pathogen-directed treatments. Further mechanistic studies are needed to clarify the pathways underlying the observed antiviral effect.